Molecular characterization and liposomal transfection of a p53-mutated cell line established from a poorly differentiated leiomyosarcoma

International Journal of Oncology

Volumn 13, Issue 2, 1998, Pages 241-248

  Meye, Axel ^a   Bache, Matthias ^a   Hinze, Raoul ^a   Schmidt, Hannelore ^a   Würl, Peter ^b   Holzhausen, Hans Jürgen ^a   Rath, Friedrich Wilhelm ^a   Taubert, Helge ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cytogenetics; Green fluorescent protein; Leiomyosarcoma cell line; Liposomal transfection; Mutational analysis immunohistochemistry; Soft tissue sarcoma

Indexed keywords

ALPHA ACTIN; CYTOKERATIN; DESMIN; GREEN FLUORESCENT PROTEIN; NEUROFILAMENT PROTEIN; PROTEIN P53; PROTEIN S 100; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SYNAPTOPHYSIN; VIMENTIN;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CASE REPORT; CYTOGENETICS; DNA TRANSFECTION; ELECTRON MICROSCOPE; FLOW CYTOMETRY; FRAMESHIFT MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

EID: 0031821640     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.2.241     Document Type: Article

References (30)

1. Enzinger FM and Weiss SW: General considerations. In: Soft Tissue Tumors. Enzinger FM and Weiss GM (eds.) St. Louis, MO, Mosby, pp1-18, 1995.
2. Fogh J and Trempe G: Human Tumor Cells In Vitro. Fogg J (ed.) Plenum Press, New York, pp115-159, 1971.
3. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
4. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Verhaug JE, Akslen LA and Lonning PE: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811-813, 1996.
5. Bristow RG, Benchimol S and Hill RP: The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 40: 197-223, 1996.
6. Würl P, Taubert H, Bache M, Kroll J, Meye A, Berger D, Sicrmann A, Holzhausen HJ, Hinze R, Schmidt H and Rath FW: Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. Int J Cancer 69: 317-323, 1996.
7. Miller CW, Aslo A, Won A, Tan M, Lampkin B and Koeffler HP: Alterations of the p53, Rb and Mdm2 genes in osteosarcoma. J Cancer Res Clin Oncol 122: 559-565, 1996.
8. Mousses S, McAuley L, Bell RS, Kandel R and Andrulis IL: Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod Pathol 9: 1-6, 1996.
9. Yoo J, Lee HK, Kang C, Park WS, Lee JY and Shim SI: p53 mutations and p53 expression in human soft tissue sarcomas. Arch Pathol Lab Med 121: 395-399, 1997.
10. Stratton MR, Moss S, Warren W, Patterson H, Clark J, Fisher C, Fletcher CD, Ball A, Thomas M, Gusterson BA and Cooper CS: Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 5: 1297-1301, 1990.
11. Varley JM, McGown G, Thorncroft M, Cochrane S, Morrison P, Woll P, Kelsey AM, Mitchell ELD, Boyle J, Birch JM and Evans DGR: A previously undescribed mutation within the tetramerisation domain of Tp53 in a family with Li-Fraumeni syndrome. Oncogene 12: 2437-2442, 1996.
12. Van Unnik JAM, Coindre JM, Contesso G, Albus-Lutter CE, Schiodt T, Garcia-Miralles T: Grading of soft-tissue sarcomas. In: Experience of the EORTC Soft Tissue and Bone Sarcoma Treatment. Ryan JR and Baker LO (eds.) Kluwer, Dortrecht, pp7-13, 1988.
13. Bache M, Dunst J, Würl P, Fröde D, Dietzel M, Meye A, Schmidt H, Rath F-W, Wohlrab W, Dralle H and Taubert H: Radiation induced G2/M block and apoptosis in two human sarcoma cell lines with different p53 gene status. Int J Oncol 11: 993-997, 1997.
14. Seabright M: A rapid banding technique for human chromosomes. Lancet ii: 971-972, 1971.
15. Verma RS and Babu A: Principles and techniques. In: Human Chromosomes. McGraw-Hill, New York, pp280-287, 1994.
16. Taubert H, Schmidt H, Würl P, Hinze R, Meye A, Bache M, Berger D, Holzhausen, H-J, Dralle H and Rath F-W: Morphological and molecular characterization of an undifferentiated soft tissue sarcoma cell line and derivative clones. Int J Oncol 11: 521-526, 1997.
17. INK4A/CDKN2/MTS1 mutations independently of p53 Status in soft tissue sarcomas. J Pathol 184: 14-17, 1998.
18. Taubert H, Meye A and Würl P: p53 mutation type type is associated with prognosis in soft tissue sarcoma patients. Cancer Res 56: 4134-4136, 1996.
19. Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, Harris CC and Montesano R: Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 25: 151-157, 1997.
20. Patterson H, Gill S, Fisher C, Law MG, Jayatilake H, Fletcher CD, Thomas M, Grimer R, Gusterson BA and Cooper CS: Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer 69: 1052-1058, 1994.
21. Stewart N, Hicks GG, Paraskevas F and Mowat M: Evidence for a second cell cycle block at G2/M by p53. Oncogene 12: 237-245, 1996.
22. Cordon-Cardo C, Latres E, Drobnjak M, Oliva M, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF and Levine A: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794-799, 1994.
23. Ladanyi M, Lewis R, Jahnwar SC, Gerald W, Huvos AG and Healey JA: MDM2 and CDK4 gene amplification in Ewing's sarcoma. J Pathol 175: 211-217, 1995.
24. Würl P, Meye A, Berger D, Bache M, Lautenschläger C, Schmidt H, Kalthoff H, Dralle H, Rath F-W and Taubert H: Prognostic relevance of C-terminal MDM2 detection is enhanced by positivity in soft tissue sarcomas. Diagn Mol Pathol 6: 249-254, 1997.
25. Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O and Fodstad O: MDM2 gene amplification and transcript levels in human sarcomas. Relationship to tp53 gene status. J Natl Cancer Inst 86: 1297-1302, 1994.
26. Sigalas I, Calvert AH, Anderson JJ, Neal DE and Lunec J: Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 2: 912-917, 1996.
27. Piette J, Neel H and Marechal V: Mdm2: keeping p53 under control. Oncogene 15: 1001-1010, 1997.
28. Schmidt H, Körber S, Hinze R, Taubert H, Meyc A, Würl P, Holzhausen H-J and Rath F-W: Cytogenetic characterization of ten malignant fibrous histiocytomas. Cancer Genet Cytogenet 100: 134-142, 1998.
29. Dei Tos AP and Dal Cin P: The role of cytogenetics in the classification of soft tissue tumors. Virchows Arch 431: 83-94, 1997.
30. Li WW, Cordon-Cardo C, Chen Q, Jhanwar SC and Bertino JR: Establishment, characterization and drug sensitivity of four new human soft tissue sarcoma cell lines. Int J Cancer 68: 514-519, 1996.